Chondrosarcoma natural history: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:


===Complications===
===Complications===
*Chondrosarcoma may metastatize to other organs.<ref name="pmid30363596">{{cite journal| author=Lalam RK, Cassar-Pullicino VN, Kumar N, Cool WP, Cribb GL, Mangham DC| title=Subcutaneous and lung metastases from chondrosarcoma of the thumb. | journal=BJR Case Rep | year= 2015 | volume= 1 | issue= 3 | pages= 20150129 | pmid=30363596 | doi=10.1259/bjrcr.20150129 | pmc=6180831 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30363596  }} </ref>
*Chondrosarcoma may [[Metastatic|metastatize]] to other [[Organ (anatomy)|organs]].<ref name="pmid30363596">{{cite journal| author=Lalam RK, Cassar-Pullicino VN, Kumar N, Cool WP, Cribb GL, Mangham DC| title=Subcutaneous and lung metastases from chondrosarcoma of the thumb. | journal=BJR Case Rep | year= 2015 | volume= 1 | issue= 3 | pages= 20150129 | pmid=30363596 | doi=10.1259/bjrcr.20150129 | pmc=6180831 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30363596  }} </ref>
*Lung is the most common location for metastatic disease.
*[[Lung]] is the most common location for [[Metastasis|metastatic]] disease.
*Chondrosarcoma can rarely metastatize to skin.<ref name="pmid30363596">{{cite journal| author=Lalam RK, Cassar-Pullicino VN, Kumar N, Cool WP, Cribb GL, Mangham DC| title=Subcutaneous and lung metastases from chondrosarcoma of the thumb. | journal=BJR Case Rep | year= 2015 | volume= 1 | issue= 3 | pages= 20150129 | pmid=30363596 | doi=10.1259/bjrcr.20150129 | pmc=6180831 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30363596  }} </ref>
*Chondrosarcoma can rarely [[Metastasis|metastatize]] to skin.<ref name="pmid30363596">{{cite journal| author=Lalam RK, Cassar-Pullicino VN, Kumar N, Cool WP, Cribb GL, Mangham DC| title=Subcutaneous and lung metastases from chondrosarcoma of the thumb. | journal=BJR Case Rep | year= 2015 | volume= 1 | issue= 3 | pages= 20150129 | pmid=30363596 | doi=10.1259/bjrcr.20150129 | pmc=6180831 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30363596  }} </ref>
*Chondrosarcoma may recur and may need treatment with [[surgery]], [[chemotherapy]] or [[radiation]].  
*Chondrosarcoma may recur and may need treatment with [[surgery]], [[chemotherapy]] or [[radiation]].  
*Unlike other cancers, chondrosarcoma can return many years later.  
*Unlike other [[cancers]], chondrosarcoma can return many years later.  
*Follow up scans are extremely important for chondrosarcoma to make sure there has been no recurrence or [[metastasis]].
*Follow up scans are extremely important for chondrosarcoma to make sure there has been no recurrence or [[metastasis]].


===Prognosis===
===Prognosis===
*The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis.<ref name="pmid10534175">{{cite journal| author=Larramendy ML, Mandahl N, Mertens F, Blomqvist C, Kivioja AH, Karaharju E et al.| title=Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas. | journal=Hum Pathol | year= 1999 | volume= 30 | issue= 10 | pages= 1247-53 | pmid=10534175 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10534175  }} </ref>
*The [[prognosis]] of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis.<ref name="pmid10534175">{{cite journal| author=Larramendy ML, Mandahl N, Mertens F, Blomqvist C, Kivioja AH, Karaharju E et al.| title=Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas. | journal=Hum Pathol | year= 1999 | volume= 30 | issue= 10 | pages= 1247-53 | pmid=10534175 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10534175  }} </ref>
**Prognosis varies with grade:<ref name="pmid890662">{{cite journal| author=Evans HL, Ayala AG, Romsdahl MM| title=Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. | journal=Cancer | year= 1977 | volume= 40 | issue= 2 | pages= 818-31 | pmid=890662 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=890662  }} </ref>
**[[Prognosis]] varies with grade:<ref name="pmid890662">{{cite journal| author=Evans HL, Ayala AG, Romsdahl MM| title=Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. | journal=Cancer | year= 1977 | volume= 40 | issue= 2 | pages= 818-31 | pmid=890662 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=890662  }} </ref>
**Grade I tumors - 90% survival at 5 years
**Grade I tumors - 90% survival at 5 years
**Grade II tumors - 81% survival at 5 years
**Grade II tumors - 81% survival at 5 years
Line 27: Line 27:
**Dedifferentiated chondrosarcoma: 10% survival rate after 1 year.
**Dedifferentiated chondrosarcoma: 10% survival rate after 1 year.
*Prognosis varies with location:<ref>{{cite book | last = Peabody | first = Terrance | title = Orthopaedic oncology : primary and metastatic tumors of the skeletal system | publisher = Springer | location = Cham | year = 2014 | isbn = 9783319073224 }}</ref>
*Prognosis varies with location:<ref>{{cite book | last = Peabody | first = Terrance | title = Orthopaedic oncology : primary and metastatic tumors of the skeletal system | publisher = Springer | location = Cham | year = 2014 | isbn = 9783319073224 }}</ref>
**Long bones have a better prognosis than axial skeleton.
**[[Long bone|Long bones]] have a better [[prognosis]] than [[axial skeleton]].


==References==
==References==

Revision as of 17:41, 24 January 2019

Chondrosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chondrosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chondrosarcoma natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chondrosarcoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chondrosarcoma natural history

CDC on Chondrosarcoma natural history

Chondrosarcoma natural history in the news

Blogs on Chondrosarcoma natural history

Directions to Hospitals Treating Chondrosarcoma

Risk calculators and risk factors for Chondrosarcoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rohan A. Bhimani, M.B.B.S., D.N.B., M.Ch.[2]

Overview

Complications that can develop as a result of chondrosarcoma are metastasis and recurrence. The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis. Chondrosarcoma is associated with a 5 year survival rate of 70%. The presence of grade 3 lesions are associated with a particularly poor prognosis.

Natural History, Complications, and Prognosis

Complications

Prognosis

  • The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis.[2]
    • Prognosis varies with grade:[3]
    • Grade I tumors - 90% survival at 5 years
    • Grade II tumors - 81% survival at 5 years
    • Grade III tumors - 29% survival at 5 years
  • Depending upon the subtype, prognosis vary substantially:[4]
    • Clear cell chondrosarcoma: 70% survival rate at 5 years.
    • Myxoid chondrosarcoma: 70% survival rate at 5 years.
    • Mesenchymal chondrosarcoma: < 50% survival rate at 5 years.
    • Dedifferentiated chondrosarcoma: 10% survival rate after 1 year.
  • Prognosis varies with location:[5]

References

  1. 1.0 1.1 Lalam RK, Cassar-Pullicino VN, Kumar N, Cool WP, Cribb GL, Mangham DC (2015). "Subcutaneous and lung metastases from chondrosarcoma of the thumb". BJR Case Rep. 1 (3): 20150129. doi:10.1259/bjrcr.20150129. PMC 6180831. PMID 30363596.
  2. Larramendy ML, Mandahl N, Mertens F, Blomqvist C, Kivioja AH, Karaharju E; et al. (1999). "Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas". Hum Pathol. 30 (10): 1247–53. PMID 10534175.
  3. Evans HL, Ayala AG, Romsdahl MM (1977). "Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading". Cancer. 40 (2): 818–31. PMID 890662.
  4. Dorfman HD, Czerniak B. Bone Tumors. St Louis: Mosby; 1998. 353-440.
  5. Peabody, Terrance (2014). Orthopaedic oncology : primary and metastatic tumors of the skeletal system. Cham: Springer. ISBN 9783319073224.